Upcoming Poster Presentations at CTOS and ESMO IO 2026
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The presentations will feature data from clinical trials of their immunotherapy candidate, eftilagimod alfa, targeting various cancers. Details include survival data from a Phase II trial at the CTOS Annual Meeting and final results from another trial at the ESMO Congress. The company aims to leverage these findings to enhance treatment options for patients and maximize shareholder value.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Receives A$2.16 million French R&D Tax Incentive
- Notice of Annual General Meeting/Proxy Form
- Appendix 4G and Corporate Governance Statement
- Annual Report to shareholders
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep